Skip to main content
. 2022 Feb;17(2):251–259. doi: 10.2215/CJN.08780621

Figure 1.

Figure 1.

Prognostic enrichment with TNF receptor-1 (TNFR-1) or TNFR-2 resulted in a decrease in sample size, an increase in the number of patients required to be screened, and an overall reduction in clinical trial costs. Figure shows the effect of prognostic enrichment with TNFR-1 or TNFR-2 on sample size, number of screenings, and costs for a future trial in the normoalbuminuria population. UACR, urinary albumin-creatinine ratio.